Mirva Hannula

M.Sc. (Pharm.)
PREP in Neurodegenerative Disorders Group Researcher
PhD student

PhD student Mirva Hannula is working with the toxin models of α-synuclein. Her project consists of the development of the rotenone model for cells and in vivo, and the use of overexpressing cells with oxidative stress.


M.Sc. (Pharm.),  University of Helsinki, 2012

  • Main subject pharmacology



Hannula MJ, Männistö PT, Myöhänen TT: Sequential expression, activity and nuclear localization of prolyl oligopeptidase in the developing rat brain. Developmental Neuroscience 33: 38-47, 2011

Myöhänen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, Baekelandt V, Männistö PT, Lambeir AM: The prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson’s disease. British Journal of Pharmacology, 166:1097-1113, 2012

Hannula MJ, Myöhänen TT, Tenorio-Laranga J, Männistö PT, Garcia-Horsman JA: Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases. Neuroscience 242:140-150, 2013

Dokleja L, Hannula MJ, Myöhänen TT: Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers. Neurosci Lett. 583C:37-42, 2014

Leave a Reply

Your email address will not be published. Required fields are marked *